Chiltern acquires Ockham and the companies merge operations - KAIT-Jonesboro, AR-News, weather, sports

Chiltern acquires Ockham and the companies merge operations

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Chiltern

LONDON and  WILMINGTON, N.C. and CARY, N.C., July 15, 2014 /PRNewswire/ -- Chiltern and Ockham, two leading full-service contract research organizations (CROs), today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

The combined company will be called Chiltern. Ockham's management team will join the management of the enlarged group, thus ensuring a seamless continuation of high quality services. Chiltern's CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham's CEO, James V. Baker, becoming Chief Development Officer. Nick Thornton will remain as Chairman.

This complementary transaction significantly strengthens the combined service offerings in three strategic areas:

  • Oncology specialization with extensive expertise across all clinical phases of development (Chiltern Oncology);
  • Biopharmaceutical services with global reach and scale, including deep therapeutic experience in respiratory, ophthalmology, infectious disease, vaccines and dermatology (Chiltern Biopharmaceutics); and
  • Global Functional Service Provider (FSP)/Sourcing provision specializing in tailored resourcing solutions across clinical, regulatory, medical and biometrics (Chiltern Source).

The combined company's clients will benefit from a fuller range of services across a global network of offices and expertise.

Chiltern CEO Dr. James Esinhart commented: "This merger is a natural progression towards our strategic goal of becoming the premier specialized mid-tier CRO. Throughout this process I have been extremely impressed by the skill and professionalism of Ockham's employees, the quality services they deliver, and the vision of the leadership team. There is a perfect strategic fit between our companies and I'm excited to work with the entire Ockham team to ensure a seamless continuation in the delivery of high quality services to all of the combined company's clients."

Mr. James V. Baker, who will become Chiltern's Chief Development Officer, echoed this sentiment in saying: "In Ockham's continuing progression toward building the top niche oncology CRO, our joining with Chiltern has been an easy choice, allowing us to leverage Chiltern's global reach and highly developed staffing business in Europe, both of which are complementary to Ockham's deep oncology expertise and source business in the US. We are fortunate to have found the ideal partner with a complete understanding and commitment to the unique needs of our emerging biotech clientele."

About Chiltern:

Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in oncology and a range of other therapeutic areas, together with global sourcing and FSP solutions. Chiltern's 2,100 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.

Further information is available at: www.chiltern.com.

Media Enquiries

FTI Consulting
John Dineen / Rob Winder
+44 (0)20 7831 3113
john.dineen@fticonsulting.com
rob.winder@fticonsulting.com

Or contact

Nicholas Spittal  
Sr. Director, Global Commercial Affairs
Chiltern International Inc. 
2528 Independence Blvd. Suite 101
Wilmington, NC 28412
USA
Tel: +1 (423) 990 0495
Email: global.marketing@chiltern.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

472 Craighead Co. 766
Jonesboro, AR 72401
(870) 931-8888

FCC Public File
publicfile@kait8.com
(870) 336-1816
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KAIT. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.